Back to news

Senti Bio Announces Reverse Stock Split

Globe Newswire•17/11/2026•08:00 ET
0

Key Highlights

  • ➤Senti Bio (SNTI) sets 1-for-33 reverse stock split effective November 18
  • ➤Split-adjusted trading begins November 19 on Nasdaq Capital Market
  • ➤Outstanding shares expected to fall from approximately 85,706,263 million to 2,597,160 million
  • ➤Nasdaq granted Senti Bio until February 23, 2027, to regain $1 minimum bid compliance
  • ➤Senti Bio says reverse split is intended to cure Nasdaq listing deficiencies

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-thirty-three (1-for-33) reverse stock split of Senti Bio’s common stock, par value $0.0001 per share (the “Common Stock”).

The reverse stock split will take effect at 5:00 p.m. EDT on November 18, 2026, and Senti Bio’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on November 19, 2026. The CUSIP number of 816944201 will be assigned to Senti Bio’s common stock when the reverse stock split becomes effective.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in